Information Regarding SARS-CoV-2 Strains and Reagents

FAQs 

Materials Available

Coming Soon

Forms
 

BEI Resources is prioritizing and fast tracking all SARS-CoV-2 registrations and orders.  We anticipate a 12-72 hour turn-around time for all SARS-CoV-2 related registrations and a 24-48 hour turn-around time on approved orders.  Please indicate SARS-CoV-2 in your scope of use in your registration paperwork.  Please contact BEI Resources at contact@beiresources.org for questions.

BEI Resources is working to accession strains of the 2019 novel coronavirus, recently named SARS-CoV-2, identified as the causative agent of an outbreak of viral pneumonia, COVID-19. We understand how important it is to share virus strains and derivatives with researchers, especially during an outbreak.

  

Currently Available SARS-CoV-2 Materials

 BEI
 Number  
 Description  Lineage  GISAID
 Clade
 GISAID ID  Clinical Information Available  Registration  
 Virus
NR-52281 SARS-CoV-2, Isolate USA-WA1/2020 A S  EPI_ISL_404895  Male in 30s, returning traveler from Wuhan. Mild disease; recovered.  BEI Level 3
NR-52282 SARS-CoV-2, Isolate Hong Kong/VM20001061/2020 A S  EPI_ISL_412028  Isolated from a nasopharyngeal aspirate and throat swab from an adult male patient on January 22, 2020 in Hong Kong  BEI Level 3
NR-52284 SARS-CoV-2, Isolate Italy-INMI1 None O  EPI_ISL_406959   (fragment) Isolated from sputum of a patient with a respiratory illness who had recently returned from travel to the affected region of China and developed clinical disease (COVID-19) in January 2020 in Rome, Italy.  BEI Level 3
NR-52359 SARS-CoV-2, Isolate England/02/2020 A S  EPI_ISL_407073  39 yr old Male;  Isolated from Nasopharyngeal aspirate & Throat swab  BEI Level 3
NR-52368 SARS-CoV-2, Isolate New York 1-PV08001/2020 B.4 O  EPI_ISL_414476 39 yr old Female;  history of travel to Iran  BEI Level 3
NR-52369 SARS-CoV-2, Isolate Singapore/2/2020 B L  EPI_ISL_407987 Isolated from a throat swab.  Patient has respiratory illness, fever and cough  BEI Level 3
NR-52370 SARS-CoV-2, Isolate Germany/BavPat1/2020 B G  EPI_ISL_406862 Isolated from Nasopharyngea swab. Typical symptoms of mild upper respiratory tract disease (D614G mutation)  BEI Level 3
NR-52381 SARS-CoV-2, Isolate USA-IL1/2020 B O  EPI_ISL_404253 63 yr old Female; Isolated from sputum  BEI Level 3
NR-52382 SARS-CoV-2, Isolate USA-CA1/2020 A S  EPI_ISL_406034 38 yr old Male; Isolated from nasopharyngeal swab  BEI Level 3
NR-52383 SARS-CoV-2, Isolate USA-AZ1/2020 A S  EPI_ISL_406223 26 yr old Male; Isolated from bucal swab  BEI Level 3
NR-52384 SARS-CoV-2, Isolate USA-WI1/2020 B L  EPI_ISL_408670 52 yr old Female; Isolated from nasopharyngeal swab  BEI Level 3
NR-52385 SARS-CoV-2, Isolate USA-CA3/2020 B L  EPI_ISL_408008 72 yr old Female; Isolated from oropharyngeal swab  BEI Level 3
NR-52386 SARS-CoV-2, Isolate USA-CA4/2020 B L  EPI_ISL_408009 57 yr old Male; Isolated from nasopharyngeal swab  BEI Level 3
NR-52387 SARS-CoV-2, Isolate USA-CA2/2020 B.2 O  EPI_ISL_406036 54 yr old Male; Isolated from nasopharyngeal swab  BEI Level 3
NR-52439 SARS-CoV-2, Isolate Chile/Santiago_op4d1/2020 A.2 S  EPI_ISL_415661 Isolated from a Nasal Swab.  Patient has respiratory tract infection. History of travel to Europe  BEI Level 3
NR-53514 SARS-CoV-2, Isolate New York-PV08410/2020 B.1 GH  EPI_ISL_421374 63 yr old Male; severe COVID19 with fatal outcome  BEI Level 3
NR-53515 SARS-CoV-2, Isolate New York-PV08449/2020 B.1 GH  EPI_ISL_421400 88 yr old Female; severe COVID19 with fatal outcome  BEI Level 3
NR-53516 SARS-CoV-2, Isolate New York-PV09158/2020 B.1.3 GH  EPI_ISL_422525 62 yr old Male; severe COVID19 with fatal outcome  BEI Level 3
NR-53517 SARS-CoV-2, Isolate New York-PV09197/2020 B.1.3 GH  EPI_ISL_422552 90 yr old Male; severe COVID19 with fatal outcome  BEI Level 3
NR-52390 Adenovirus Serotype 5, Clone Ad5-CMV-hACE2/RSV-eGFP, Recombinant Expressing Human ACE2  BEI Level 2
 Nucleic Acid
NR-52285 Genomic RNA from SARS-CoV-2, Isolate USA-WA1/2020  BEI Level 2
NR-52388 Genomic RNA from SARS-CoV-2, Isolate Hong Kong/VM20001061/2020  BEI Level 2
NR-52498 Genomic RNA from SARS-CoV-2, Isolate Italy-INMI1   BEI Level 2
NR-52501 Genomic RNA from SARS-CoV-2, Isolate Singapore/2/2020   BEI Level 2
NR-52502 Genomic RNA from SARS-CoV-2, Isolate Germany/BavPat1/2020   BEI Level 2
NR-52503 Genomic RNA from SARS-CoV-2, Isolate USA-IL1/2020   BEI Level 2
NR-52505 Genomic RNA from SARS-CoV-2, Isolate USA-AZ1/2020   BEI Level 2
NR-52506 Genomic RNA from SARS-CoV-2, Isolate USA-WI1/2020   BEI Level 2
NR-52507 Genomic RNA from SARS-CoV-2, Isolate USA-CA3/2020   BEI Level 2
NR-52508 Genomic RNA from SARS-CoV-2, Isolate USA-CA4/2020   BEI Level 2
NR-52509 Genomic RNA from SARS-CoV-2, Isolate USA-CA2/2020   BEI Level 2
NR-52358 Quantitative Synthetic RNA from SARS-CoV-2  BEI Level 1
NR-52346 Quantitative PCR (qPCR) Control RNA from Inactivated SARS Coronavirus, Urbani  BEI Level 1
NR-52347 Quantitative PCR (qPCR) Control RNA from Heat-Inactivated SARS-CoV-2, Isolate USA-WA1/2020  BEI Level 1
 Inactivated Organisms
NR-52286 SARS-CoV-2, Isolate USA-WA1/2020, Heat Inactivated   BEI Level 1
NR-52349 Quantitative PCR (qPCR) Extraction Control from Inactivated SARS Coronavirus, Urbani   BEI Level 1
NR-52350 Quantitative PCR (qPCR) Extraction Control from Heat-Inactivated SARS-CoV-2, Isolate USA-WA1/2020   BEI Level 1
 Cell Line
NR-52511 Human Embryonic Kidney Cells (HEK-293T) Expressing Human Angiotensin-Converting Enzyme 2, HEK-293T-hACE2 Cell Line   BEI Level 2
NR-53258 Vero E6 Cell Lysate Control, Gamma-Irradiated (To be used with NR-52287)    BEI Level 1
NR-53522 Human Lung Carcinoma Cells (A549) Expressing Human Angiotensin-Converting Enzyme 2 (HA-FLAG)   BEI Level 1
 Monoclonal Antibody
NR-52481 Monoclonal Anti-SARS Coronavirus Recombinant Human Antibody, Clone CR3022 (produced in HEK293 Cells)   BEI Level 1
NR-53787 Monoclonal Anti-SARS Coronavirus Spike Glycoprotein S1 Domain (produced in vitro  BEI Level 1
NR-53788 Monoclonal Anti-SARS-CoV-2 Spike Glycoprotein S1 Domain (produced in vitro  BEI Level 1
NR-53789 Monoclonal Anti-SARS Coronavirus/SARS-CoV-2 Spike Glycoprotein Receptor Binding Domain (RBD), Chimeric Antibody (produced in vitro  BEI Level 1
NR-53790 Monoclonal Anti-SARS Coronavirus/SARS-CoV-2 Spike Glycoprotein Receptor Binding Domain (RBD), Chimeric Antibody (produced in vitro  BEI Level 1
NR-53791 Monoclonal Anti-SARS Coronavirus/SARS-CoV-2 Nucleocapsid Protein, rabbit MAb (produced in vitro  BEI Level 1
NR-53792 Monoclonal Anti-SARS Coronavirus/SARS-CoV-2 Nucleocapsid Protein, mouse MAb (produced in vitro)  BEI Level 1
NR-53793 Monoclonal Anti-SARS-CoV-2 Nucleocapsid Protein (produced in vitro)  BEI Level 1
NR-53794 Monoclonal Anti-SARS Coronavirus/SARS-CoV-2 Nucleocapsid Protein (produced in vitro)  BEI Level 1
NR-53795 Monoclonal Anti-SARS-CoV-2 Spike Glycoprotein RBD-mFc Fusion Protein (produced in vitro)  BEI Level 1
NR-53796 Monoclonal Anti-SARS-CoV-2 Spike RBD-mFc Fusion Protein (produced in vitro)  BEI Level 1
 Serum/Plasma
NR-52401 Pooled Non-Human Primate Convalescent Serum to SARS-CoV-2, Gamma-Irradiated   BEI Level 2
NR-52947 Polyclonal Anti-SARS-CoV-2 Spike Glycoprotein (IgG, Rabbit)   BEI Level 1
 Protein
NR-52307 Spike Glycoprotein RBD from SARS-CoV-2, Wuhan-Hu-1 with C-Terminal Histidine Tag, Recombinant from Baculovirus  BEI Level 1
NR-52308 Spike Glycoprotein (Stabilized) from SARS-CoV-2, Wuhan-Hu-1 with C-Terminal Histidine Tag, Recombinant from Baculovirus (This item replaces NR-52396)   BEI Level 1
NR-52366 Spike Glycoprotein RBD from SARS-CoV-2, Wuhan-Hu-1 with C-Terminal Histidine Tag, Recombinant from HEK293 Cells (This item replaces NR-52306)  BEI Level 1
NR-52724 Spike Glycoprotein (Stabilized) from SARS-CoV-2, Wuhan-Hu-1 with C-Terminal Histidine and Twin-Strep® Tags, Recombinant from HEK293 Cells 
(related product for NR-53257)  
 BEI Level 1
NR-52946 Spike Glycoprotein RBD from SARS-CoV-2, Wuhan-Hu-1 with C-Terminal Histidine Tag, Recombinant from HEK293T Cells  BEI Level 1
NR-53246 Nucleocapsid Protein N-Terminal RNA Binding Domain from SARS-CoV-2, Wuhan-Hu-1 with N-Terminal Histidine Tag, Recombinant from E. coli  BEI Level 1
NR-53524 Spike Glycoprotein (Stabilized) from SARS-CoV-2, Wuhan-Hu-1 with C-Terminal Histidine and Avi Tags, Recombinant from HEK293F Cells   BEI Level 1
NR-53589 Spike Glycoprotein (Stabilized) from SARS-CoV-2, Wuhan-Hu-1 with C-Terminal Histidine and Twin-Strep® Tags, Recombinant from HEK293 Cells   BEI Level 1
NR-53769 Spike Glycoprotein (Stabilized) from SARS-CoV-2, Wuhan-Hu-1 HexaPro with C-Terminal Histidine and Twin-Strep® Tags, Recombinant from CHO Cells   BEI Level 1
NR-53797 Nucleocapsid Protein from SARS-CoV-2, Wuhan-Hu-1 with C-Terminal Histidine Tag, Recombinant from Baculovirus   BEI Level 1
NR-53798 Spike Glycoprotein S1 Domain from SARS-CoV-2, Wuhan-Hu-1 with C-Terminal Histidine Tag, Recombinant from HEK293 Cells   BEI Level 1
NR-53799 Spike Glycoprotein S2 Extracellular Domain (ECD) from SARS-CoV-2, Wuhan-Hu-1 with C-Terminal Histidine Tag, Recombinant from Baculovirus   BEI Level 1
NR-53800 Spike Glycoprotein Receptor Binding Domain (RBD) from SARS-CoV-2, Wuhan-Hu-1 with C-Terminal Histidine Tag, Recombinant from HEK293 Cells   BEI Level 1
 Peptide Array
NR-52402 Peptide Array, SARS-CoV-2 Spike (S) Glycoprotein   BEI Level 1
NR-52403 Peptide Array, SARS-CoV-2 Membrane (M) Protein   BEI Level 1
NR-52404 Peptide Array, SARS-CoV-2 Nucleocapsid (N) Protein   BEI Level 1
NR-52405 Peptide Array, SARS-CoV-2 Envelope (E) Protein   BEI Level 1
NR-52419 Peptide Array, SARS Coronavirus Nucleocapsid (N) Protein   BEI Level 1
 Plasmid
NR-52948 SARS-CoV-2, Wuhan-Hu-1 Spike-Pseudotyped Lentiviral Kit    BEI Level 1
NR-53260 Plasmid Set for Anti-SARS Coronavirus Human Monoclonal Antibody CR3022    BEI Level 1
NR-52309 Vector pCAGGS Containing the SARS-CoV-2, Wuhan-Hu-1 Spike Glycoprotein Gene RBD with C-Terminal Hexa-Histidine Tag   BEI Level 1
NR-52310 Vector pCAGGS Containing the SARS-CoV-2, Wuhan-Hu-1 Spike Glycoprotein Gene   BEI Level 1
NR-52394 Vector pCAGGS Containing the SARS-CoV-2, Wuhan-Hu-1 Spike Glycoprotein Gene (soluble, stabilized)  BEI Level 1
NR-52420 Vector pcDNA3.1(-) Containing the SARS-CoV-2, Wuhan-Hu-1 Spike Glycoprotein Gene   BEI Level 1
NR-52421 Vector pCMV Containing the SARS-CoV-2, Wuhan-Hu-1 Spike Glycoprotein Ectodomain   BEI Level 1
NR-52422 Vector pcDNA3.1(-) Containing the SARS-CoV-2, Wuhan-Hu-1 Spike Glycoprotein RBD   BEI Level 1
NR-52423 Vector pMCSG53 Containing the SARS-CoV-2, Wuhan-Hu-1 SARS-CoV Unique Domain Gene   BEI Level 1
NR-52424 Vector pMCSG53 Containing the SARS-CoV-2, Wuhan-Hu-1 Non-Structural Protein 9 Gene    BEI Level 1
NR-52425 Vector pMCSG53 Containing the SARS-CoV-2, Wuhan-Hu-1 Non-Structural Protein 10 Gene   BEI Level 1
NR-52426 Vector pMCSG53 Containing the SARS-CoV-2, Wuhan-Hu-1 Non-Structural Protein 15 Gene   BEI Level 1
NR-52427 Vector pMCSG53 Containing the SARS-CoV-2, Wuhan-Hu-1 Non-Structural Protein 16 Gene   BEI Level 1
NR-52428 Vector pMCSG53 Containing the SARS-CoV-2, Wuhan-Hu-1 Spike Glycoprotein N-Terminal Domain   BEI Level 1
NR-52429 Vector pMCSG53 Containing the SARS-CoV-2, Wuhan-Hu-1 Nucleocapsid Protein RNA Binding Domain Gene   BEI Level 1
NR-52430 Vector pMCSG53 Containing the SARS-CoV-2, Wuhan-Hu-1 Spike Glycoprotein RBD   BEI Level 1
NR-52431 Vector pET-11a Containing the SARS-CoV-2, Wuhan-Hu-1 Non-Structural Protein 8 Gene   BEI Level 1
NR-52432 Vector pET-11a Containing the SARS-CoV-2, Wuhan-Hu-1 Non-Structural Protein 7 Gene   BEI Level 1
NR-52433 Vector pET-11a Containing the SARS-CoV-2, Wuhan-Hu-1 Non-Structural Protein 14 Gene   BEI Level 1
NR-52434 Vector pET-11a Containing the SARS-CoV-2, Wuhan-Hu-1 Nucleocapsid Protein C-Terminal Domain Gene   BEI Level 1
NR-52435 Vector pET-11a Containing the SARS-CoV-2, Wuhan-Hu-1 Non-Structural Protein 4 Gene, Cytoplasmic C-Terminal Domain   BEI Level 1
NR-52512 Vector pHAGE2 Containing the Angiotensin-Converting Enzyme 2 Gene   BEI Level 1
NR-52513 Vector pHDM Containing the SARS-CoV-2, Wuhan-Hu-1 Spike Glycoprotein Ectodomain Mutant, HA Tag   BEI Level 1
NR-52515 Vector pHDM Containing the SARS-CoV-2, Wuhan-Hu-1 Spike Glycoprotein Ectodomain Mutant ALAYT   BEI Level 1
NR-52520 Vector pHAGE2 Containing the ZsGreen Gene   BEI Level 1
NR-52563 Modified pαH Vector Containing the SARS-CoV-2, Wuhan-Hu-1 Spike Glycoprotein Ectodomain   BEI Level 1
NR-52564 Modified pαH Vector Containing the SARS-CoV-2, Wuhan-Hu-1 Spike Glycoprotein   BEI Level 1
NR-52565 Modified pαH Vector Containing the Human Angiotensin-Converting Enzyme 2   BEI Level 1
NR-52897 Vector pMCSG53 Containing the SARS-CoV-2, Wuhan-Hu-1 Papain-Like Protease Gene   BEI Level 1
NR-52898 Vector pCSGID Containing the SARS-CoV-2, Wuhan-Hu-1 3C-Like Protease Gene   BEI Level 1
NR-52899 Vector pMCSG53 Containing the SARS-CoV-2, Wuhan-Hu-1 Non-Structural Protein 1 Gene   BEI Level 1
NR-52900 Vector pMCSG53 Containing the SARS-CoV-2, Wuhan-Hu-1 Non-Structural Protein 7 Gene   BEI Level 1
NR-52901 Vector pMCSG120 Containing the SARS-CoV-2, Wuhan-Hu-1 Non-Structural Protein 8 Gene   BEI Level 1
NR-52902 Vector pMCSG53 Containing the SARS-CoV-2, Wuhan-Hu-1 Non-Structural Protein 8 Gene   BEI Level 1
NR-52949 Vector pLVX-EF1α-IRES-Puro Containing the SARS-CoV-2, USA-WA1/2020 Non-Structural Protein 1 Gene   BEI Level 1
NR-52950 Vector pLVX-EF1α-IRES-Puro Containing the SARS-CoV-2, USA-WA1/2020 Non-Structural Protein 2 Gene   BEI Level 1
NR-52951 Vector pLVX-EF1α-IRES-Puro Containing the SARS-CoV-2, USA-WA1/2020 Non-Structural Protein 4 Gene   BEI Level 1
NR-52953 Vector pLVX-EF1α-IRES-Puro Containing the SARS-CoV-2, USA-WA1/2020 3C-Like Protease Gene, C145A Mutant   BEI Level 1
NR-52955 Vector pLVX-EF1α-IRES-Puro Containing the SARS-CoV-2, USA-WA1/2020 Non-Structural Protein 7 Gene   BEI Level 1
NR-52956 Vector pLVX-EF1α-IRES-Puro Containing the SARS-CoV-2, USA-WA1/2020 Non-Structural Protein 8 Gene   BEI Level 1
NR-52957 Vector pLVX-EF1α-IRES-Puro Containing the SARS-CoV-2, USA-WA1/2020 Non-Structural Protein 9 Gene   BEI Level 1
NR-52958 Vector pLVX-EF1α-IRES-Puro Containing the SARS-CoV-2, USA-WA1/2020 Non-Structural Protein 10 Gene   BEI Level 1
NR-52959 Vector pLVX-EF1α-IRES-Puro Containing the SARS-CoV-2, USA-WA1/2020 Non-Structural Protein 11 Gene   BEI Level 1
NR-52960 Vector pLVX-EF1α-IRES-Puro Containing the SARS-CoV-2, USA-WA1/2020 Non-Structural Protein 12 Gene   BEI Level 1
NR-52961 Vector pLVX-EF1α-IRES-Puro Containing the SARS-CoV-2, USA-WA1/2020 Non-Structural Protein 13 Gene   BEI Level 1
NR-52962 Vector pLVX-EF1α-IRES-Puro Containing the SARS-CoV-2, USA WA1/2020 Non-Structural Protein 14 Gene   BEI Level 1
NR-52963 Vector pLVX-EF1α-IRES-Puro Containing the SARS-CoV-2, USA-WA1/2020 Non-Structural Protein 15 Gene   BEI Level 1
NR-52965 Vector pLVX-EF1α-IRES-Puro Containing the SARS-CoV-2, USA-WA1/2020 Open Reading Frame 3a Gene   BEI Level 1
NR-52966 Vector pLVX-EF1α-IRES-Puro Containing the SARS-CoV-2, USA-WA1/2020 Open Reading Frame 3b Gene   BEI Level 1
NR-52967 Vector pLVX-EF1α-IRES-Puro Containing the SARS-CoV-2, USA-WA1/2020 Envelope Gene   BEI Level 1
NR-52968 Vector pLVX-EF1α-IRES-Puro Containing the SARS-CoV-2, USA-WA1/2020 Membrane Glycoprotein Gene   BEI Level 1
NR-52970 Vector pLVX-EF1α-IRES-Puro Containing the SARS-CoV-2, USA-WA1/2020 Open Reading Frame 7a Gene   BEI Level 1
NR-52971 Vector pLVX-EF1α-IRES-Puro Containing the SARS-CoV-2, USA-WA1/2020 Open Reading Frame 7b Gene  BEI Level 1
NR-52972 Vector pLVX-EF1α-IRES-Puro Containing the SARS-CoV-2, USA-WA1/2020 Open Reading Frame 8 Gene  BEI Level 1
NR-52973 Vector pLVX-EF1α-IRES-Puro Containing the SARS-CoV-2, USA-WA1/2020 Nucleocapsid Gene  BEI Level 1
NR-52974 Vector pLVX-EF1α-IRES-Puro Containing the SARS-CoV-2, USA-WA1/2020 Open Reading Frame 9b Gene  BEI Level 1
NR-52975 Vector pLVX-EF1α-IRES-Puro Containing the SARS-CoV-2, USA-WA1/2020 Open Reading Frame 9c Gene  BEI Level 1
NR-52976 Vector pLVX-EF1α-IRES-Puro Containing the SARS-CoV-2, USA-WA1/2020 Open Reading Frame 10 Gene   BEI Level 1
NR-52977 Vector pLVX-EF1α-IRES-Puro Containing the Enhanced Green Fluorescent Protein   BEI Level 1
NR-53496 Vector pET-28a(+) Containing the SARS-CoV-2, Wuhan-Hu-1 Non-Structural Protein 1 Gene   BEI Level 1
NR-53497 Vector pET-28a(+) Containing the SARS-CoV-2, Wuhan-Hu-1 Non-Structural Protein 4 Gene   BEI Level 1
NR-53498 Vector pET-28a(+) Containing the SARS-CoV-2, Wuhan-Hu-1 Non-Structural Protein 6 Gene   BEI Level 1
NR-53499 Vector pET-28a(+) Containing the SARS-CoV-2, Wuhan-Hu-1 Non-Structural Protein 7 Gene   BEI Level 1
NR-53500 Vector pET-28a(+) Containing the SARS-CoV-2, Wuhan-Hu-1 Non-Structural Protein 8 Gene   BEI Level 1
NR-53501 Vector pET-28a(+) Containing the SARS-CoV-2, Wuhan-Hu-1 Non-Structural Protein 9 Gene   BEI Level 1
NR-53502 Vector pET-28a(+) Containing the SARS-CoV-2, Wuhan-Hu-1 Non-Structural Protein 10 Gene   BEI Level 1
NR-53503 Vector pFastbac1 Containing the SARS-CoV-2, Wuhan-Hu-1 Non-Structural Protein 12 Gene    BEI Level 1
NR-53504 Vector pET-28a(+) Containing the SARS-CoV-2, Wuhan-Hu-1 Non-Structural Protein 13 Gene    BEI Level 1
NR-53505 Vector pET-28a(+) Containing the SARS-CoV-2, Wuhan-Hu-1 Non-Structural Protein 14 Gene    BEI Level 1
NR-53506 Vector pET-28a(+) Containing the SARS-CoV-2, Wuhan-Hu-1 Non-Structural Protein 15 Gene    BEI Level 1
NR-53507 Vector pET-28a(+) Containing the SARS-CoV-2, Wuhan-Hu-1 Nucleocapsid Gene    BEI Level 1
NR-53508 Vector pET-28a(+) Containing the SARS-CoV-2, Wuhan-Hu-1 Membrane Glycoprotein Gene    BEI Level 1
NR-53509 Vector pET-28a(+) Containing the SARS-CoV-2, Wuhan-Hu-1 Open Reading Frame 3a Gene    BEI Level 1
NR-53510 Vector pET-28a(+) Containing the SARS-CoV-2, Wuhan-Hu-1 Open Reading Frame 7a Gene    BEI Level 1
NR-53511 Vector pET-28a(+) Containing the SARS-CoV-2, Wuhan-Hu-1 Non-Structural Protein 16 Gene    BEI Level 1
NR-53587 Modified pαH Vector Containing the SARS-CoV-2, Wuhan-Hu-1 HexaPro Spike Glycoprotein Ectodomain    BEI Level 1
NR-53696 Vector pCMV/R Containing the SARS-CoV-2, Wuhan-Hu-1 Spike Glycoprotein Gene    BEI Level 1

 

We anticipate a large number of requests from the research community for these reagents, and we cannot guarantee how quickly stock will become available. Please continue checking for updates.

If you wish to transfer SARS-CoV-2 materials, please use the guidance provided in the Emergency Use Simple Letter Agreement.

  

Coming Soon and Expected Availability

 Item Number   Description  Expected Availability 
 Virus
 NR-53565  SARS-CoV-2, Isolate hCoV/Canada/ON/VIDO-01/2020  November
 NR-53749  SARS-CoV-2, USA/WA1/2020 wild type  November
 NR-53750  SARS-CoV-2, USA/WA1/2020 -eGFP  November
 NR-53751  SARS-CoV-2, USA/WA1/2020- nanoluciferase  November
 Nucleic Acid
 NR-52389  Genomic RNA from SARS-CoV-2, Isolate New York-PV08001/2020  October
 NR-52499  Genomic RNA from SARS-CoV-2, Isolate England/02/2020  October
 NR-52504  Genomic RNA from SARS-CoV-2, Isolate USA-CA1/2020  October
 Inactivated Organisms
 NR-52287  SARS-CoV-2, Isolate USA-WA1/2020, Gamma-Irradiated  Mid-November
 Monoclonal Antibody
 NR-52392  Monoclonal Anti-SARS Coronavirus Recombinant Human IgG1, Clone CR3022 (produced in Nicotiana benthamiana  Early 2021 
 NR-53876  Anti-SARS-CoV human monoclonal antibody, CR3022   November 
 Protein
 NR-52397  Spike Glycoprotein (Stabilized) from SARS-CoV-2, Wuhan-Hu-1 with C-Terminal Histidine Tag, Recombinant from HEK293F Cells   Late October 
 NR-52348  Spike Glycoprotein from SARS-CoV-2, Wuhan-Hu-1, Recombinant from HEK293T Cells   October
 Peptide Array
 NR-52418  Peptide Array SARS-CoV S Protein (Peptides 1 to 169)   November 
 Plasmid
 NR-52969  Plasmid pLVX-EF1α-IRES-Puro SARS-CoV-2, orf6 (TST)   October

 

The BEI Resources catalog offers additional coronavirus materials ready and available for distribution to qualified laboratories.

For access to BEI Resources full catalog, click here.

 

Frequently Asked Questions 

  1. Is there currently a shortage or delay in receiving SARS-CoV-2 virus isolates or RNA from BEI Resources?
  2. How long will it take to get SARS-CoV-2 materials?
  3. How long will it take to process my registration to receive SARS-CoV-2 materials?
  4. Who is qualified to receive SARS-CoV-2 materials?
  5. What level of registration do I need to receive SARS-CoV-2 materials?
  6. If I have questions regarding SARS-CoV-2 materials, who do I contact?
  7. How much do SARS-CoV-2 materials cost?
  8. What is the Emergency Use Simple Letter Agreement (EUSLA)?
  9. Which SARS-CoV-2 materials distributed by BEI fall under the EUSLA?
  10. Can I transfer SARS-CoV-2 materials?
  11. Can I commercialize SARS COV-2 materials?
  12. Are COVID-19 patient samples currently available from BEI Resources?
  13. How do I obtain test kits for COVID-19?
  14. Why is the SARS-CoV-2 genomic RNA only distributed to facilities which have BSL-2 laboratories?
  15. Am I required to obtain a CDC permit for the transfer of SARS-CoV-2 isolates?
  16. Where do I find product documentation (Product Sheet, Certificate of Analyses, etc.) for BEI Resources products?
  17. How do I find out about SARS-CoV-2 products coming soon?

 

Question: Is there currently a shortage or delay in receiving SARS-CoV-2 virus isolates or RNA from BEI Resources?

Answer: No, BEI Resources currently does not have a shortage or a delay in shipping virus and RNA to qualified laboratories. We understand how important it is to share virus strains and derivatives with researchers, especially during an outbreak.

Back to Questions

 

Question: How long will it take to get SARS-CoV-2 materials?

Answer: BEI Resources is prioritizing all SARS-CoV-2 shipments.  Shipments are generally being made within 24-48 hours of completed requests.  If permits are required, these timelines are dependent on obtaining those permits.  Please contact us at contact@beiresources.org for any shipment questions.

Back to Questions

 

Question: How long will it take to process my registration to receive SARS-CoV-2 materials?

Answer: BEI Resources is prioritizing and fast tracking all SARS-CoV-2 registrations.  We anticipate a 12-72 hour turn-around time for all SARS-CoV-2 related registrations.  Please indicate SARS-CoV-2 in your scope of use.  Please contact BEI Resources at contact@beiresources.org for questions.

Back to Questions

 

Question: Who is qualified to receive SARS-CoV-2 materials?

Answer: Registration with BEI Resources is required to request SARS-CoV-2 materials. BEI Resources reagents are shared with registered individuals and organizations doing research on Emerging Infections and other relevant areas of interest related to Microbiology. To register you must be affiliated with a public, private, academic, non-profit or for-profit institution. Registrants must demonstrate they work in an established institution with facilities and safety programs appropriate for the Level of registration requested.

Back to Questions

 

Question: What level of registration do I need to receive SARS-CoV-2 materials?

Answer: Each product on the BEI Resources website lists a BEI Resources level of registration.  Interested researchers will need to ensure they are registered at the appropriate level to receive materials.  Please click here for registration instructions.  If you need to upgrade your registration to a higher level, please click here for instructions.

Back to Questions

 

Question: If I have questions regarding SARS-CoV-2 materials, who do I contact?

Answer: Please contact BEI Resources at contact@beiresources.org for any questions regarding SARS-CoV-2 materials.

Back to Questions

 

Question: How much do SARS-CoV-2 materials cost?

Answer: All BEI Resources reagents, including SARS-CoV-2 materials, are provided world-wide at no cost. While there is no cost for the reagents themselves, additional shipping and handling charges may apply and will display in the shopping cart if applicable.

Back to Questions

 

Question: What is the Emergency Use Simple Letter Agreement (EUSLA)?

Answer: The Emergency Use Simple Letter Agreement outlines the terms in which SARS-CoV-2 materials are being provided.  In light of the emergence of the novel coronavirus, 2019-SARS-CoV-2, and urgent need to mitigate the pathogen’s spread, the EUSLA was instituted for the provision of these materials under the terms outlined in the agreement. The EUSLA is not negotiable.

Back to Questions

 

Question: Which SARS-CoV-2 materials distributed by BEI fall under the EUSLA?

Answer: The viruses, nucleic acids, and inactivated SARS-CoV-2 organisms, along with the gamma irradiated NHP convalescent serum from SARS-CoV-2, are distributed under the terms of the EUSLA. Please note that the signature of the biosafety officer to certify that your facility can safely handle the material is required for receipt of the virus. The following is a list of items distributed by BEI under the EUSLA:

 

 Item Number   Description
 NR-52281  SARS-CoV-2, Isolate USA-WA1/2020
 NR-52282  SARS-CoV-2, Isolate Hong Kong/VM20001061/2020
 NR-52284  SARS-CoV-2, Isolate Italy-INMI1
 NR-52359  SARS-CoV-2, Isolate England/02/2020
 NR-52368  SARS-CoV-2, Isolate New York 1-PV08001/2020
 NR-52369  SARS-CoV-2, Isolate Singapore/2/2020
 NR-52370  SARS-CoV-2, Isolate Germany/BavPat1/2020
 NR-52381  SARS-CoV-2, Isolate USA-IL1/2020
 NR-52382  SARS-CoV-2, Isolate USA-CA1/2020
 NR-52383  SARS-CoV-2, Isolate USA-AZ1/2020
 NR-52384  SARS-CoV-2, Isolate USA-WI1/2020
 NR-52385  SARS-CoV-2, Isolate USA-CA3/2020
 NR-52386  SARS-CoV-2, Isolate USA-CA4/2020
 NR-52387  SARS-CoV-2, Isolate USA-CA2/2020
 NR-52439  SARS-CoV-2, Isolate Chile/Santiago_op4d1/2020
 NR-53514  SARS-CoV-2, Isolate New York-PV08410/2020
 NR-53515  SARS-CoV-2, Isolate New York-PV08449/2020
 NR-53516  SARS-CoV-2, Isolate New York-PV09158/2020
 NR-53517  SARS-CoV-2, Isolate New York-PV09197/2020
 NR-52285  Genomic RNA from SARS-CoV-2, Isolate USA-WA1/2020
 NR-52388  Genomic RNA from SARS-CoV-2, Isolate Hong Kong/VM20001061/2020
 NR-52498  Genomic RNA from SARS-CoV-2, Isolate Italy-INMI1
 NR-52501  Genomic RNA from SARS-CoV-2, Isolate Singapore/2/2020
 NR-52502  Genomic RNA from SARS-CoV-2, Isolate Germany/BavPat1/2020
 NR-52503  Genomic RNA from SARS-CoV-2, Isolate USA-IL1/2020
 NR-52505  Genomic RNA from SARS-CoV-2, Isolate USA-AZ1/2020
 NR-52506  Genomic RNA from SARS-CoV-2, Isolate USA-WI1/2020
 NR-52507  Genomic RNA from SARS-CoV-2, Isolate USA-CA3/2020
 NR-52508  Genomic RNA from SARS-CoV-2, Isolate USA-CA4/2020
 NR-52509  Genomic RNA from SARS-CoV-2, Isolate USA-CA2/2020
 NR-52347  Quantitative PCR (qPCR) Control RNA from Heat-Inactivated SARS-CoV-2, Isolate USA-WA1/2020
 NR-52286  SARS-CoV-2, Isolate USA-WA1/2020, Heat Inactivated 
 NR-52287  SARS-CoV-2, Isolate USA-WA1/2020, Gamma-Irradiated 
 NR-52350  Quantitative PCR (qPCR) Extraction Control from Heat-Inactivated SARS-CoV-2, Isolate USA-WA1/2020 
 NR-52401  Pooled Non-Human Primate Convalescent Serum to SARS-CoV-2, Gamma-Irradiated 
 NR-53593 - NR-53692   SARS-CoV-2, Human Plasma and PBMC Samples
 NR-53736  SARS-CoV-2, Human Peripheral Blood Mononuclear Cells (PBMC), Subject ID: LPEQAP142
 NR-53737  SARS-CoV-2, Human Plasma, Subject ID: LPEQAP142
 NR-53738  SARS-CoV-2, Human Serum, Subject ID: 0873-294

 

Back to Questions

 

Question: Can I transfer SARS-CoV-2 materials?

Answer: “Material” as used in this answer, means the original material or any unmodified progeny received from BEI Resources. SARS-CoV-2 materials received under the EUSLA may be further distributed to other entities for legitimate purposes required to rapidly prevent, detect, prepare for, and respond to, the spread or transmission of SARS-CoV-2 and under terms no more restrictive than the Emergency Use Simple Letter Agreement (EUSLA). To ensure compliance with this, copies of the EUSLA or MTAs recording all further transfers must be sent back to contact@beiresources.org. This requirement must also be incorporated for further transfers. The recipient and provider agree to transfer, use, manage, and control the SARS-CoV-2 materials in compliance with all applicable laws and regulations. When these commodities, technology or software are exported from the United States, the recipient agrees to comply with the Export Administration Regulations. Diversion contrary to U.S. law is prohibited.

Any products made by you, that are not considered the original material or unmodified progeny, are excluded from this requirement, and you are free to share and commercialize those products as your own products.

Back to Questions

 

Question: Can I commercialize SARS COV-2 materials? 

Answer: “Material” as used in this answer, means the original material or any unmodified progeny received from BEI Resources. SARS-CoV-2 materials received under the EUSLA are made available for any legitimate purpose, including commercial purposes, as long as they are to rapidly prevent, detect, prepare for, and respond to, the spread or transmission of the 2019 SARS-CoV-2. Any transfer of the original material or any unmodified progeny must be done under the terms of the EUSLA (see question above regarding transfer of SARS-CoV-2 materials). Any products made by you, that are not considered the original material or unmodified progeny, are excluded from this requirement, and you are free to share and commercialize those products as your own products.

Back to Questions

 

Question: Are COVID-19 patient samples currently available from BEI Resources?

Answer: We understand how important it is to share patient samples, including sera, nasal swabs and PBMCs, with researchers, especially during an outbreak. We will have a very limited number of samples available. Requestors must limit their orders to 5 samples of serum/plasma. We anticipate a large number of requests from the research community for patient samples related to the pandemic, and will continually work towards making more samples available. Please order according to the limits above and contact our email box at contact@beiresources.org with any questions. If we are not able to fill your needs, please contact us so we can forward your request to NIAID to prioritize those samples once available.

Back to Questions

 

Question: How do I obtain test kits for COVID-19?

Answer: Test kits are not distributed through BEI Resources. The CDC 2019-Novel Coronavirus (2019-nCoV) Real-Time RT-PCR Diagnostic Panel was developed for qualified domestic public health laboratories to detect SARS-CoV-2. The U.S. Food and Drug Administration (FDA) issued an Emergency Use Authorization (EUA) on February 4, 2020, to enable emergency use of the test kit in the United States. CDC has produced EUA and Research Use Only (RUO) test kits that are now available to order by domestic and international public health partners through IRR (www.internationalreagentresource.org). Please contact the International Reagent Resources program for more information – contact@internationalreagentresource.org.

Back to Questions

 

Question: Why is the SARS-CoV-2 genomic RNA only distributed to facilities which have BSL-2 laboratories?

Answer: CDC guidelines state that molecular analysis of extracted nucleic acid preparations should be performed in BSL-2 facility using standard BSL-2 work practices. The CDC guidelines can be found in the following link: https://www.cdc.gov/coronavirus/2019-nCoV/lab/lab-biosafety-guidelines.html

Back to Questions

 

Question: Am I required to obtain a CDC permit for the transfer of SARS-CoV-2 isolates

Answer: The BEI Resources website provides a link on each product detail page for applicable permits. Please check the individual product detail pages for this information. SARS-CoV-2 isolates which originate from the United States do not require a CDC permit for domestic transfer. SARS-CoV-2 isolates which are deposited into BEI Resources outside of the USA, will be brought into the repository under a CDC permit, and will require a CDC permit for transfer.

Back to Questions 

 

Question: Where do I find product documentation (Product Sheet, Certificate of Analyses, etc.) for BEI Resources products?

Answer: All Product Sheets and Certificates of Analysis can be found on the BEI Resources website. Perform a search for the product, and you will find the documentation. Any product listed as requiring a BSL-3 facility, will require login first to view the documentation. Only BEI Level 3 registrants will have access to view and download products requiring BSL-3 facilities.

Back to Questions 

 

Question: How do I find out about SARS-CoV-2 products coming soon?

Answer: BEI Resources will list the status of SARS-CoV-2 products coming soon in the table above titled Coming Soon and Expected Availability.

Back to Questions 

 

Forms

Emergency Use Simple Letter Agreement (EUSLA)

 

Back to the top

View More Highlights